Abstract
Fucose sugars are expressed on mammalian cell
membranes as part of glycoconjugates and mediates essential physiological processes.
The aberrant expression of fucosylated glycans has been linked to pathologies such
as cancer, inflammation, infection, and genetic disorders. Tools to modulate
fucose expression on living cells are needed to elucidate the biological role
of fucose sugars and the development of potential therapeutics. Herein, we
report a novel class of fucosylation inhibitors directly targeting de novo GDP-fucose biosynthesis. We demonstrate that cell permeable
fluorinated mannoside 1-phosphate derivatives (Fucotrim I & II) are
metabolic prodrugs that are metabolized to their respective GDP-mannose
derivatives and efficiently inhibit cellular fucosylation.
Supplementary materials
Title
Fucotrim Supplementary information
Description
Actions